|
|
News Breaks | | | | December 14, 2012 | | 08:36 EDT |  | RIGL | Rigel still poised to report good fostamatinib results, says Stifel Nicolaus
After Rigel Pharmaceuticals reported that its fostamatinib drug for rheumatoid arthritis.had failed to demonstrate non-inferiority versus a competing drug, Stifel reports that the results don't alter its forecast for fostamatinib's Phae III trials. The firm thinks the decline in Rigel's stock following the results were overdone and it maintains a Buy rating. | |
|
News For RIGL From The Last 14 Days Check below for free stories on RIGL the last two weeks. |
|
|
| May 22, 2013 | | 07:34 EDT |  | RIGL | Rigel Pharmaceuticals to initiate Phase 2 clinical trial in dry eye
 Subscribe for More Information | |
|
|
|
|
|
|
